A prospective survey was conducted on 862 Enterobacteriaceae with reduced susceptibility to carbapenems. The Carba NP test, UV spectrophotometry and DNA microarray were used for detecting carbapenemase producers, and results compared to PCR and sequencing. The 172 carbapenemase producers were detected using the Carba NP test and UV spectrophotometry whereas DNA microarray failed to detect IMI producers. Use of the Carba NP test as first screening, followed by the use of molecular techniques has been defined as an efficient strategy for identification of carbapenemaseproducing Enterobacteriaceae.
Carbapenemases lead to the ultimate evolution of resistance in Enterobacteriaceae, leaving virtually very few efficient antibiotics left (1, 2). The most clinically-significant carbapenemases in Enterobacteriaceae are: (i) Ambler class A enzymes including KPC, IMI and SME enzymes (1, 3, 4), (ii) metallo-β-lactamases (MBL) of VIM-, IMP-and NDM-types (5, 6) , and (iii) OXA-48-like enzymes (7) . Detection of carbapenemase producers include screening of patients at risk to be carriers of carbapenemase producers including patients who have been hospitalized abroad and implementation of efficient isolation procedures for carriers are the main features for limiting the spread of this emerging resistance trait (8) (9) (10) .
The biochemical Carba NP test, based on detection of carbapenem hydrolysis has been recently developed (11) . Molecular methods such as simplex and multiplex PCRs, DNA hybridization and sequencing are also used for the identification of carbapenemase genes.
The aim of this study was to evaluate prospectively an efficient and cost-effective strategy for detection and characterization of carbapenemase-producing Enterobacteriaceae.
From June 2011 to July 2012, 862 non-duplicate clinical Enterobacteriaceae isolates from worldwide origin were tested for characterization of the mechanisms leading to reduced susceptibility to carbapenems (Figure 1 ). The isolates were identified using MALDI-TOF mass spectrometry (Vitek MS, bioMérieux, La Balme-les-Grottes, France). Susceptibility testing was performed by determining MIC values using the Etest ® (bioMérieux) on Mueller-
Hinton agar plates at 37°C and results were recorded according to US guidelines (CLSI), as updated in 2013 (12) . All tested isolates were non susceptible to at least one of the three carbapenem molecules, imipenem, meropenem, or ertapenem.
Detection of bla KPC , bla IMI , bla SME , bla GES , bla VIM , bla IMP , bla NDM , bla GIM , and bla OXA-48 carbapenemase genes was performed by simplex PCR followed by sequencing (13) . Results of PCR and sequencing were used as standards for the evaluation of the other detection techniques. A molecular detection of the β-lactamase genes was also performed for all carbapenemase producers (n=173) using a DNA hybridization array approach (Check-MDR CT103 array; Check-Points, Wageningen, The Netherlands) following the manufacturer instructions (16) .
Detection of carbapenemase production was performed by UV spectrophometry as previously described (14) . It was also performed by using the Carba NP test (11 Among the 862 enterobacterial isolates tested, the PCR-based techniques followed by sequencing identified 172 carbapenemase producers. As compared to the PCR-based detection method, the UV spectrophotometry method and the Carba NP test were found to be 100% sensitive and 100% specific for detecting carbapenemase producers (Table 1) . Since the bla IMI gene was not included in the panel of carbapenemase genes detected by the Check-MDR CT103, this array failed to identify the two Enterobacter spp. strains producing the IMI-1 carbapenemase, leading to a 98.8% sensitivity and 100% specificity ( Table 1 ). The positive predictive values (PPV) were of 100 % for all the three techniques and negative predictive values (NPV) were of 100 % for UV spectrophotometry and Carba NP test, and of 99.7 % for the Check-MDR CT103 array (Table 1 ).
The DNA array was the only technique that could identify additional noncarbapenemase β-lactamases. Indeed, 70% of the carbapenemase-producing
Enterobacteriaceae additionally expressed at least one broad-spectrum β-lactamase, such as a plasmid-mediated cephalosporinase and/or an extended-spectrum ß-lactamase (Table 2) .
Among the 172 carbapenemase producers, 65% were Klebsiella pneumoniae, 15%
were Escherichia coli, 13% were Enterobacter spp., 5% were Citrobacter freundii, 1% were Serratia marcescens and 1% were Salmonella enterica ( Table 2 ). The identified carbapenemases were of the OXA-48-(72%), KPC-(15%), NDM-(6%), VIM-(6%) and IMI-types (1%) ( Table 2 ). The characterization of carbapenemase genes was done by sequencing as listed in Table 2 . Regardless of the enterobacterial species considered, OXA-48-like carbapenemases were predominant in our collection (Figure 1 ). KPC producers were mostly identified in K. pneumoniae compared to the other enterobacterial species (96%, p<0.001). On the opposite, NDM producers were equally distributed (p>0.05) among each type of enterobacterial species (Figure 1 ).
Overall, this study showed 100% specificity and sensitivity for the Carba NP test and UV spectrophotometry to detect the production of a carbapenemase (Table 1) (11) .
Additionally, the PPV and NPV of both techniques were also 100 %. The Carba NP test was as efficient as the UV spectrophotometry method to detect carbapenemase producers but with significant advantages, since the Carba NP test is more rapid (<2h versus 24 h for UV spectrophotometry) and does not require any specific training. Its cost is less than 1 US$ per tested strain whereas UV spectrophotometric assay and PCR-based techniques require additional equipment (UV spectrophotometer and sonicator for the UV spectrophotometric assay, consumables, reagents, and thermocycler for PCR assay). On the other hand, the Check-MDR CT103 failed to detect two IMI-1 producers, leading to 100% specificity, 98.8% sensitivity, 100% PPV and 99.7% NPV (Table 1 and Table 2 and PCR-based testing (30 US$). However, the microarray technique may help to characterize the entire β-lactamase content of a single isolate by detecting also other broad-spectrum β-lactamase genes.
The diversity of carbapenemases identified here mirrors the worldwide dissemination of the four main described enzymes (KPC, VIM, NDM and OXA-48) (1). Additionally, our results further highlight the wide dissemination of the OXA-48 carbapenemase in Europe (particularly in France) accounting for 72% of the whole carbapenemases (Figure 1 ) (7, 17) , whereas KPC is the most widespread carbapenemase in the US. Of note, the KPC carbapenemases are nearly restricted to the K. pneumoniae species (25/26). On the opposite, OXA-48 and NDM were distributed among all enterobacterial species.
Since the management of patients requires a rapid identification of carbapenemase producers (regardless of its type) (18), a diagnostic strategy for detection of carbapenemase producers in Enterobacteriaceae is proposed here (Figure 2 ). This strategy is based on: (i) the Carba NP test as the primary screening test for detection of a carbapenemase production, followed by (ii) a specific molecular characterization of the carbapenemase genes by simplex PCRs or DNA microarray. The initial step (susceptibility testing and Carba NP test) may be developed in any laboratory worldwide. Molecular identification of the carbapenemase genes may be also performed locally depending on the molecular techniques available, however it is not required for antibiotic stewardship or infection control purposes.
In case of a negative result obtained with the Carba NP test, the mechanism responsible for carbapenem decreased susceptibility is not related to the production of a carbapenemase (e.g. reduced permeability of the outer membrane associated with over-expression of chromosomal or acquired AmpC and/or ESBL), therefore no additional test is required (17) . In case of positive result with the Carba NP test, the use of a set of five simplex PCR (bla KPC , bla VIM , bla NDM , bla IMI and bla OXA-48-like ) may then identify all carbapenemase genes of our collection ( Figure 1 , Table 2 ). However, this screening may be adapted to the local epidemiology as recently proposed for the detection of carbapenemase SME in the US (4). The DNA microarray may be more useful for epidemiological purposes or for infection control studies when high numbers of isolates have to be rapidly characterized (16) .
Additionally, this procedure may also detect potential new carbapenemases. Indeed, although molecular techniques are currently considered as "gold standard" for detection of carbapenemase producers, they are only able to detect known carbapenemase genes. With the proposed strategy, a positive Carba NP test followed by negative results using molecular thechniques may correspond to a novel carbapenemase that may be further characterize using cloning experiments (Figure 2 ). This is the first prospective study evaluating at an international level the value of the different techniques for detecting carbapenemases. The strategy proposed for detection of carbapenemase producers presents several advantages for treating infected patients and for isolation of carriers. Indeed, it will lead to a rapid identification of carbapenemase producers (< 2 h) using the Carba NP test, allowing a better antibiotic stewardship (18) . This strategy may also have a significant impact for preventing the development of nosocomial outbreaks by acting rapidly on the management of carriers (isolation, cohorting) as demonstrated for KPC outbreaks at least in Israel (19). Finally, since the first step of this strategy which includes susceptibility testing and the Carba NP test is based on cheap techniques, it may be followed worldwide, and therefore contribute to Bold arrows indicate the preferred way for identification of carbapenemase genes. This second step may be followed only in University hospitals or large-size microbiology laboratories. 
